

Dr. Giuseppe Ronzitti is head of the Immunology and Liver gene transfer (IMF) team at Genethon and a tenured INSERM researcher at the UMR_S951 "INTEGRARE". He has a PhD in Biochemistry and experience in neuroscience and gene therapy for rare genetic diseases. Along his career, Dr Ronzitti authored more than sixty research articles and seventeen patents on the development of AAV-based gene therapy strategies.

In his current position, he is scientific co-coordinator of the CureCN grant, sponsoring with Genethon a Crigler-Najjar syndrome clinical trial that is now in phase III (NCT03466463). He is also responsible for the preclinical development of two new AAV gene therapy products for GSDIa and GSDIII. The IMF team is focused on three distinct research areas coordinated by experienced researchers under the supervision of Dr. Ronzitti. The main core expertise of the laboratory is on metabolic diseases, but the team has also expertise in immunology of AAV gene transfer as well as in the engineering of AAV capsids and transgene expression cassettes.